Global HLA Typing for Transplant Market by Product & Service (Instruments, Reagents & Consumables, Software & Services), Technology (Molecular Assay Technologies, Non-Molecular Assay Technologies), Transplant Type, Application, End-User - Forecast 2023-2030- Product Image

Sale

Global HLA Typing for Transplant Market by Product & Service (Instruments, Reagents & Consumables, Software & Services), Technology (Molecular Assay Technologies, Non-Molecular Assay Technologies), Transplant Type, Application, End-User - Forecast 2023-2030

Report
196 Pages
March 2024
Region: Global
360iResearch™
ID: 5674350

UP TO €846EUR$875USD£727GBP OFF until Dec 31^st 2024

The HLA Typing for Transplant Market size was estimated at USD 919.00 million in 2022, USD 998.31 million in 2023, and is expected to grow at a CAGR of 9.04% to reach USD 1,836.58 million by 2030.

Human leukocyte antigen (HLA) typing is a vital process in medicine transplant that involves identifying specific proteins on the surface of cells, known as HLA antigens. The HLA typing for the transplant is used to identify, match, and monitor compatibility between donors and recipients for organ, tissue, or stem cell transplantation. This process is crucial to ensure a successful transplant by reducing the risk of graft rejection and improving overall patient outcomes. Moreover, the rising demand for organ transplants is due to an increase in chronic diseases such as kidney failure, liver cirrhosis, heart failure, diabetes mellitus, and hematological disorders. Precision medicine advancements can lead to personalized approaches based on individual genetic makeup for improved compatibility between donors and recipients. However, there is a need for more trained professionals performing these tests and ethical concerns surrounding organ transplantation consent policies, which restrict the growth of the Human leukocyte antigen (HLA) processes. Furthermore, technological advancements in HLA typing methods such as Next-Generation Sequencing (NGS), PCR-based techniques, and Sanger sequencing contribute to improved accuracy and a faster donor-recipient matching process. Government support through awareness campaigns promoting organ donation and investments in healthcare infrastructure further drive market expansion.

Regional Insights

The Human leukocyte antigen (HLA) typing for transplant market is experiencing significant growth worldwide due to technological advancements and the availability of numerous organ transplant procedures. In the United States and Canada, demand for HLA typing is increasing due to growing organ transplantation needs. The National Institutes of Health (NIH) in the U.S. has funded numerous research initiatives to improve HLA typing techniques. Moreover, the Americas human leukocyte antigen (HLA) typing market is expected to grow at a higher rate due to increasing awareness about organ transplantation among both physicians and patients, along with technological advancements leading to more accurate HLA typing results. Europe has witnessed a steady increase in demand for HLA typing services owing to factors such as an aging population that increases the prevalence of chronic diseases requiring organ transplantation. Additionally, favorable reimbursement policies have supported patients undergoing transplant procedures in Europe. Organizations such as the Saudi Society for Organ Transplantation (SSOT) are working to increase awareness and collaborations between nations, such as the Gulf Cooperation Council (GCC) Organ Transplant Program. China, Japan, and India are witnessing an increased demand for HLA typing due to a high prevalence of genetic disorders and growing organ transplantation needs. China's National Natural Science Foundation has funded research on novel HLA typing techniques. Moreover, Japan's Ministry of Health, Labor, and Welfare supports projects such as the Japan Society for Transplantation and Cellular Therapy (JSTCT). In India, government initiatives, such as the 'National Organ and Tissue Transplant Organization (NOTTO) contribute to market growth by increasing public awareness about organ donation.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the HLA Typing for Transplant Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the HLA Typing for Transplant Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the HLA Typing for Transplant Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., BAG Diagnostics GmbH, Becton, Dickinson, and Company, BGI Genomics Co.,Ltd., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, CapitalBio Technology Co., Ltd., CareDx, Inc., CeGaT GmbH, Chugai Pharmaceutical Co., Ltd., Creative Biolabs, Inc., DiaSorin S.p.A., Eurofins Scientific SE, F. Hoffman-La Roche AG, Fujirebio, Inc. by H.U. Group Holdings, Inc., Garuda Therapeutics, GenDx by Eurobio Scientific Group, HEALIOS K.K., Hologic, Inc., Illumina, Inc., Immatics N.V., Immucor, Inc. by Werfen, S.A., ImmunOs Therapeutics AG, Invectys Inc., Laboratory Corporation of America Holdings, Lonza Group Ltd., Merck KGaA, NeoGenomics Laboratories, Inc., OraSure Technologies, Inc., Oxford Nanopore Technologies PLC, Pure MHC, LLC, Pure Protein, LLC, QIAGEN N.V., STEMCELL Technologies Inc., T-Cure Bioscience Inc., Takara Bio Inc., TBG Diagnostics Ltd., TCR² Therapeutics by Adaptimmune Therapeutics PLC, and Thermo Fisher Scientific, Inc.

Market Segmentation & Coverage

This research report categorizes the HLA Typing for Transplant Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product & Service
- Instruments
- Reagents & Consumables
- Software & Services
Technology
- Molecular Assay Technologies
  - PCR-Based Molecular Assays
    - Real-Time PCR
    - Sequence-Specific Oligonucleotide-PCR
    - Sequence-Specific Primer-PCR
  - Sequencing-Based Molecular Assays
    - Next-Generation Sequencing
    - Sanger Sequencing
- Non-Molecular Assay Technologies
Transplant Type
- Organ Transplantation
- Stem Cell Transplantation
- Tissue Transplantation
Application
- Diagnostic Applications
  - Antibody Screening
  - Chimerism Monitoring
- Research Applications
End-User
- Clinical Laboratories & Research Institution
- Hospitals & Transplant Centers
- Independent Reference Laboratories

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the HLA Typing for Transplant Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the HLA Typing for Transplant Market?
What are the technology trends and regulatory frameworks in the HLA Typing for Transplant Market?
What is the market share of the leading vendors in the HLA Typing for Transplant Market?
Which modes and strategic moves are suitable for entering the HLA Typing for Transplant Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. HLA Typing for Transplant Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of bone marrow, organ, and blood transplant processes
5.1.1.2. Adoption of HLA typing in personalized medicine for reduced graft rejections
5.1.2. Restraints
5.1.2.1. Lack of reimbursement and inadequate insurance policies
5.1.3. Opportunities
5.1.3.1. Technological advancements in the field of transplant diagnostics and HLA-typing methods
5.1.3.2. Preference for immunosuppressive therapies to complement HLA typing
5.1.4. Challenges
5.1.4.1. Concerns regarding the inaccuracy of HLA typing
5.2. Market Segmentation Analysis
5.2.1. Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility
5.2.2. Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow
5.2.3. Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases
5.2.4. Application: Use of HLA typing in diagnostic applications for organ transplantation
5.2.5. End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability
5.3. Market Trend Analysis
5.3.1. Advanced Healthcare R&D and presence of established market vendors facilitate the expansion of HLA typing in Americas
5.3.2. Dynamically expanding HLA typing for transplant market in the APAC, with emphasis on advanced technology adoption for offering improved healthcare infrastructure for transplantation
5.3.3. Rising need for transplant procedures and government support for commercializing quality HLA typing to create a favorable market landscape in EMEA
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. HLA Typing for Transplant Market, by Product & Service

6.1. Introduction
6.2. Instruments
6.3. Reagents & Consumables
6.4. Software & Services

7. HLA Typing for Transplant Market, by Technology

7.1. Introduction
7.2. Molecular Assay Technologies
7.3.1. PCR-Based Molecular Assays
7.3.2.1. Real-Time PCR
7.3.2.2. Sequence-Specific Oligonucleotide-PCR
7.3.2.3. Sequence-Specific Primer-PCR
7.3.2. Sequencing-Based Molecular Assays
7.3.3.1. Next-Generation Sequencing
7.3.3.2. Sanger Sequencing
7.3. Non-Molecular Assay Technologies

8. HLA Typing for Transplant Market, by Transplant Type

8.1. Introduction
8.2. Organ Transplantation
8.3. Stem Cell Transplantation
8.4. Tissue Transplantation

9. HLA Typing for Transplant Market, by Application

9.1. Introduction
9.2. Diagnostic Applications
9.3.1. Antibody Screening
9.3.2. Chimerism Monitoring
9.3. Research Applications

10. HLA Typing for Transplant Market, by End-User

10.1. Introduction
10.2. Clinical Laboratories & Research Institution
10.3. Hospitals & Transplant Centers
10.4. Independent Reference Laboratories

11. Americas HLA Typing for Transplant Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific HLA Typing for Transplant Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa HLA Typing for Transplant Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Merger & Acquisition
14.3.1.1. Eurobio Scientific acquires GenDx for USD 132.3 million
14.3.2. Agreement, Collaboration, & Partnership
14.3.2.1. JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer
14.3.2.2. Ossium Health and Be The Match Unveil Partnership to Increase Bone Marrow Transplant Accessibility and Treatment Efficiency
14.3.2.3. Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
14.3.2.4. Be The Match BioTherapies, Atara Biotherapeutics Ink Multi-Year Partnership Extension
14.3.3. New Product Launch & Enhancement
14.3.3.1. GenDx launches NGS-Turbo: revolutionizing high-resolution HLA typing with Oxford Nanopore Technologies sequencing devices
14.3.3.2. Omixon Launches NanoTYPE MONO and MONOall RUO, a Singleplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION Platform
14.3.3.3. Metropolis Healthcare unveils NextGen HLA test for organ transplantation
14.3.3.4. CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service
14.3.3.5. FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma
14.3.4. Investment & Funding
14.3.4.1. BriaCell receives NCI grant for cancer platform development
14.3.4.2. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform

15. Competitive Portfolio

15.1. Key Company Profiles
15.1.1. Agilent Technologies, Inc.
15.1.2. BAG Diagnostics GmbH
15.1.3. Becton, Dickinson, and Company
15.1.4. BGI Genomics Co.,Ltd.
15.1.5. Bio-Rad Laboratories, Inc.
15.1.6. Bio-Techne Corporation
15.1.7. CapitalBio Technology Co., Ltd.
15.1.8. CareDx, Inc.
15.1.9. CeGaT GmbH
15.1.10. Chugai Pharmaceutical Co., Ltd.
15.1.11. Creative Biolabs, Inc.
15.1.12. DiaSorin S.p.A.
15.1.13. Eurofins Scientific SE
15.1.14. F. Hoffman-La Roche AG
15.1.15. Fujirebio, Inc. by H.U. Group Holdings, Inc.
15.1.16. Garuda Therapeutics
15.1.17. GenDx by Eurobio Scientific Group
15.1.18. HEALIOS K.K.
15.1.19. Hologic, Inc.
15.1.20. Illumina, Inc.
15.1.21. Immatics N.V.
15.1.22. Immucor, Inc. by Werfen, S.A.
15.1.23. ImmunOs Therapeutics AG
15.1.24. Invectys Inc.
15.1.25. Laboratory Corporation of America Holdings
15.1.26. Lonza Group Ltd.
15.1.27. Merck KGaA
15.1.28. NeoGenomics Laboratories, Inc.
15.1.29. OraSure Technologies, Inc.
15.1.30. Oxford Nanopore Technologies PLC
15.1.31. Pure MHC, LLC
15.1.32. Pure Protein, LLC
15.1.33. QIAGEN N.V.
15.1.34. STEMCELL Technologies Inc.
15.1.35. T-Cure Bioscience Inc.
15.1.36. Takara Bio Inc.
15.1.37. TBG Diagnostics Ltd.
15.1.38. TCR² Therapeutics by Adaptimmune Therapeutics PLC
15.1.39. Thermo Fisher Scientific, Inc.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing

List of Figures

FIGURE 1. HLA TYPING FOR TRANSPLANT MARKET RESEARCH PROCESS
FIGURE 2. HLA TYPING FOR TRANSPLANT MARKET SIZE, 2022 VS 2030
FIGURE 3. HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. HLA TYPING FOR TRANSPLANT MARKET DYNAMICS
FIGURE 7. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2022 VS 2030 (%)
FIGURE 8. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
FIGURE 10. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2022 VS 2030 (%)
FIGURE 12. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 14. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 16. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 20. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 25. HLA TYPING FOR TRANSPLANT MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 26. HLA TYPING FOR TRANSPLANT MARKET SHARE, BY KEY PLAYER, 2022

List of Tables

TABLE 1. HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 6. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 10. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 12. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 14. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 19. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 23. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TISSUE TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 27. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 29. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ANTIBODY SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CHIMERISM MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CLINICAL LABORATORIES & RESEARCH INSTITUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 65. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 66. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 67. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 68. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 69. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 70. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 72. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 76. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 112. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 113. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 114. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 115. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 116. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 117. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 119. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 121. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 123. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 124. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 125. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 126. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 128. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 130. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 132. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 133. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 134. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 139. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 141. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 142. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 143. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 144. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 146. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 148. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 150. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 151. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 152. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 157. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 159. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 160. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 161. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 166. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 168. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 169. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 170. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 171. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 175. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 176. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 177. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 178. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 179. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 180. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 184. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 192. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 193. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 194. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 195. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 196. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 197. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 198. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 200. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 202. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 203. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 204. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 205. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 206. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 207. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 220. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 221. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 222. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 223. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 224. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 225. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 226. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 228. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 230. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 231. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 232. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 233. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 234. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 235. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 237. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 238. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 239. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 240. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 241. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 242. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 244. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 246. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 247. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 248. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 249. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 250. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 251. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 252. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 253. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 255. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 257. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 258. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 259. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 260. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 261. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 262. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 264. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 274. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 275. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 276. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 277. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 278. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 279. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 280. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 282. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 292. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 293. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 294. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 295. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 296. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 297. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 298. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 299. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 301. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
TABLE 302. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 303. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 304. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 305. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
TABLE 306. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
TABLE 307. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABL

Companies Mentioned

Agilent Technologies, Inc.
BAG Diagnostics GmbH
Becton, Dickinson, and Company
BGI Genomics Co.,Ltd.
Bio-Rad Laboratories, Inc.
Bio-Techne Corporation
CapitalBio Technology Co., Ltd.
CareDx, Inc.
CeGaT GmbH
Chugai Pharmaceutical Co., Ltd.
Creative Biolabs, Inc.
DiaSorin S.p.A.
Eurofins Scientific SE
F. Hoffman-La Roche AG
Fujirebio, Inc. by H.U. Group Holdings, Inc.
Garuda Therapeutics
GenDx by Eurobio Scientific Group
HEALIOS K.K.
Hologic, Inc.
Illumina, Inc.
Immatics N.V.
Immucor, Inc. by Werfen, S.A.
ImmunOs Therapeutics AG
Invectys Inc.
Laboratory Corporation of America Holdings
Lonza Group Ltd.
Merck KGaA
NeoGenomics Laboratories, Inc.
OraSure Technologies, Inc.
Oxford Nanopore Technologies PLC
Pure MHC, LLC
Pure Protein, LLC
QIAGEN N.V.
STEMCELL Technologies Inc.
T-Cure Bioscience Inc.
Takara Bio Inc.
TBG Diagnostics Ltd.
TCR² Therapeutics by Adaptimmune Therapeutics PLC
Thermo Fisher Scientific, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	196
Published	March 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 998.31 Million
Forecasted Market Value ( USD ) by 2030	$ 1836.58 Million
Compound Annual Growth Rate	9.0%
Regions Covered	Global
No. of Companies Mentioned	39

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3262EUR$3,374USD£2,804GBP €3624EUR$3,749USD£3,115GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4132EUR$4,274USD£3,551GBP €4591EUR$4,749USD£3,946GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5002EUR$5,174USD£4,299GBP €5558EUR$5,749USD£4,777GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5872EUR$6,074USD£5,047GBP €6524EUR$6,749USD£5,608GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7612EUR$7,874USD£6,543GBP €8458EUR$8,749USD£7,270GBP

Regional Insights

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Kits, Software), Application (Antibody Screening), Type (Organ Transplant, Tissue), End User, and Region - Forecast to 2028

HLA Typing for Transplant Market Report: Trends, Forecast and Competitive Analysis to 2030

Global HLA Typing Market by Technology (Molecular Assay Technologies, Non-Molecular Assay Technology), Products (Instruments, Reagents & Consumables, Software & Services), Application, End-User - Forecast 2024-2030

HLA Typing for Transplant Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

HLA Typing for Transplant - Global Strategic Business Report